Through reporter gene screening, we identified signaling transduction and activation transcription 3 (STAT3) activation as a novel compensatory pathway for the potential therapeutic resistance of ESCC to ERK signaling inhibition. Here, STAT3 is linked to esophageal squamous cell carcinoma.